Replies to post #15787 on Cel Sci Corporation (CVM)

[Spideyboy]

I am getting numbers closer to yours, and will take into account he 42% you mention from Phase II.

Phase II percentage data I think is relatively skewed as the sample was small.

As mentioned I'll look at this closer tomorrow, but at this time I would prefer to use the public survival data and the 10% calculation of benefit, as the public survival data comes from a much larger cohort than the Phase II data.